BioSpace News Archive

Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory and data firm focused on the developing cannabis and hemp markets, is pleased to announce its support of Congress’s Farm Bill, which legalizes the production and sale of hemp.

CVS Health (NYSE: CVS) today announced that MinuteClinic, the company’s retail medical clinic, has rolled out its new virtual health care offering in the state of Wyoming.

Chardan, a global investment bank, announced today that the peer-reviewed journal, Human Gene Therapy Clinical Development, published a perspective authored by analysts in the firm’s equity research department.

IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced the discovery of new immune system triggers that are associated with certain inflammatory diseases.

Immuno-Oncology experts PD Dr. Jessica Hassel (National Center for Tumor Diseases, Heidelberg, Germany) and Dr. Aurélien Marabelle (Gustave Roussy, Paris, France)

ArTara Therapeuticss, a clinical-stage company developing treatments for rare diseases with significant unmet needs, today announced that it has successfully completed an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) to discuss study of Intravenous (IV) Choline Chloride substrate replacement for patients with Intestinal Failure Associated Liver Disease (IFALD).

Three distinct datasets were used in the manuscript to validate the EDGE platform as a robust machine-learning tool for neoantigen identification.

Would you buy your groceries without knowing the price? How about that new pair of jeans you’ve been coveting for months? The answer is a resounding no!

Pharmadis received rights to market Genetic Immunity’s HIV technology in Russia and the Commonwealth of Independent States

Agreement for the KCI iOn PROGRESS™ Remote Therapy Monitoring Program which aims to improve overall patient experience, while lowering costs through increased engagement and adherence.